This is the authors' abstract. We don't add key points for this paper.
After progression on EGFR-TKI, patients with EGFR-mutated NSCLC show substantial benefit on different chemotherapy regimens. In particular, favorable outcomes were seen in patients treated with PP and CPBA as first-line chemotherapy, and PB in further lines of chemotherapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Steendam et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: